Eli Lilly and Company will unveil data from more than 50 studies at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. from May 29 to June 2, 2009. Majority of the presentations are learnt to support Lilly's leadership in thoracic cancer research. The company will present the latest research findings on Alimta (pemetrexed for injection), as well as Gemzar (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy.
This year's ASCO also marks the first time Lilly will feature the newest molecules in its portfolio resulting from Lilly's recent acquisition of ImClone Systems.
"ASCO's theme of 'Personalizing Cancer Care' is one to which Lilly has subscribed for many years," said Richard Gaynor, Lilly vice president, cancer research and global oncology platform leader. "We are focused on delivering what we call 'tailored therapies' - an essential component of personalized medicine - to identify patients who are most likely to respond to therapy, and just as importantly, which patients will not."
"With ASCO studies focusing on non-small cell lung cancer, breast cancer, cervical cancer and biliary tract cancer, among others, Lilly will demonstrate its continued commitment to meeting the needs of patients across a broad oncology spectrum," Richard informed.